Latest News
-
HBS Reporting
Novartis drug shown to ease symptoms of painful skin condition
Sep 22, 2022FRANKFURT, Sept 10 (Reuters) – Novartis said its anti-inflammatory drug Cosentyx eased the symptoms of a...
-
HBS Reporting
FDA warns of potential clip lock issue with Abbott’s heart valve repair device
Sep 9, 2022Sept 8 (Reuters) – The U.S. Food and Drug Administration on Thursday alerted healthcare providers about...
-
HBS Reporting
Long COVID’s link to suicide: scientists warn of hidden crisis
Sep 9, 2022The 56-year-old, who caught the disease in spring 2020, still had not recovered about 18 months...
-
HBS Reporting
Grifols in 15-year deal with Canada for plasma-based medicines
Sep 9, 2022Sept 7 (Reuters) – Spanish pharmaceutical company Grifols (GRLS.MC) has struck a 15-year renewable collaboration agreement...
-
HBS Reporting
Bharat Biotech’s COVID-19 nasal vaccine approved for restricted use in India
Sep 9, 2022NEW DELHI, Sept 6 (Reuters) – Bharat Biotech’s COVID-19 recombinant nasal vaccine has been approved by...
-
HBS Reporting
Updated COVID vaccines to be ready this week, U.S. eyes annual shots
Sep 9, 2022WASHINGTON, Sept 6 (Reuters) – New COVID-19 boosters aimed at fighting currently circulating variants of the...
-
HBS Reporting
CVS expects ‘meaningful’ tax benefit from Signify acquisition
Sep 9, 2022Sept 6 (Reuters) – CVS Health Corp (CVS.N) said on Tuesday it expects “meaningful” tax benefits...
-
HBS Reporting
Taiwan to resume visa free entry for some countries in latest reopening step
Sep 9, 2022TAIPEI, Sept 5 (Reuters) – Taiwan will resume visa free entry for visitors from countries including...
-
HBS Reporting
Boost high-risk people with Omicron-tailored shots first – EU officials
Sep 9, 2022LONDON, Sept 6 (Reuters) – EU officials on Tuesday recommended that the two Omicron- tailored vaccines...
-
HBS Reporting
Russia reports 50,000 COVID-19 cases for second day running
Sep 5, 2022Sept 3 (Reuters) – Russia recorded more than 50,000 new daily COVID-19 cases for the second...